Suppression of TLR signaling by targeting TIR domain-containing proteins

Current Protein and Peptide Science

Volumn 13, Issue 8, 2012, Pages 776-788

  Fekonja, Ota ^a   Avbelj, Monika ^a,b   Jerala, Roman ^a,b,c  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b EN FIST Centre of Excellence   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Decoy peptides; Inhibitory tir domain containing proteins; Peptidomimetics; Therapeutic inhibition; Tlr signaling

Indexed keywords

CELL PENETRATING PEPTIDE; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDOMIMETIC AGENT; PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSCRIPTION FACTOR;

APOPTOSIS; ATHEROSCLEROSIS; DIMERIZATION; EMPHYSEMA; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INTERNALIZATION; MYRISTYLATION; NEOPLASM; NONHUMAN; OLIGOMERIZATION; PROTEIN DOMAIN; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; HUMANS; IMMUNITY, INNATE; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84874847135     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920312804871148     Document Type: Review

References (141)

1. Beutler, B. Innate immunity: an overview. Mol. Immunol., 2004, 40(12), 845-859.
2. Janeway, C. A., Jr.; Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol., 2002, 20, 197-216.
3. Janeway, C. A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp. Quant. Biol., 1989, 54 Pt 1, 1-13.
4. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol., 2004, 4(7), 499-511.
5. Rock, F. L.; Hardiman, G.; Timans, J. C.; Kastelein, R. A.; Bazan, J. F. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA., 1998, 95(2), 588-593.
6. Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C. A., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388(6640), 394-397.
7. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell, 2006, 124(4), 783-801.
8. Ishii, K. J.; Coban, C.; Akira, S. Manifold mechanisms of Toll-like receptor-ligand recognition. J. Clin. Immunol., 2005, 25(6), 511-521.
9. Gay, N. J.; Gangloff, M. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem., 2007, 76, 141-165.
10. Jerala, R. Structural biology of the LPS recognition. Int. J. Med. Microbiol., 2007, 297(5), 353-363.
11. Kim, H. M.; Park, B. S.; Kim, J. I.; Kim, S. E.; Lee, J.; Oh, S. C.; Enkhbayar, P.; Matsushima, N.; Lee, H.; Yoo, O. J.; Lee, J. O. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell, 2007, 130(5), 906-917.
12. Park, B. S.; Song, D. H.; Kim, H. M.; Choi, B. S.; Lee, H.; Lee, J. O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 2009, 458(7242), 1191-1195.
13. Gay, N. J.; Keith, F. J. Drosophila Toll and IL-1 receptor. Nature, 1991, 351(6325), 355-356.
14. Schneider, D. S.; Hudson, K. L.; Lin, T. Y.; Anderson, K. V. Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal-ventral polarity in the Drosophila embryo. Genes Dev., 1991, 5(5), 797-807.
15. Slack, J. L.; Schooley, K.; Bonnert, T. P.; Mitcham, J. L.; Qwarnstrom, E. E.; Sims, J. E.; Dower, S. K. Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways. J. Biol. Chem., 2000, 275(7), 4670-4678.
16. O'Neill, L. A.; Bowie, A. G. The family of five: TIR-domaincontaining adaptors in Toll-like receptor signalling. Nat. Rev. Immunol., 2007, 7(5), 353-364.
17. Yamamoto, M.; Sato, S.; Hemmi, H.; Uematsu, S.; Hoshino, K.; Kaisho, T.; Takeuchi, O.; Takeda, K.; Akira, S. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol., 2003, 4(11), 1144-1150.
18. Oshiumi, H.; Sasai, M.; Shida, K.; Fujita, T.; Matsumoto, M.; Seya, T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferonbeta. J. Biol. Chem., 2003, 278(50), 49751-49762.
19. Yamamoto, M.; Sato, S.; Hemmi, H.; Sanjo, H.; Uematsu, S.; Kaisho, T.; Hoshino, K.; Takeuchi, O.; Kobayashi, M.; Fujita, T.; Takeda, K.; Akira, S. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature, 2002, 420(6913), 324-329.
20. Horng, T.; Barton, G. M.; Medzhitov, R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol., 2001, 2(9), 835-841.
21. Carty, M.; Goodbody, R.; Schroder, M.; Stack, J.; Moynagh, P. N.; Bowie, A. G. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol., 2006, 7(10), 1074-1081.
22. Kawai, T.; Adachi, O.; Ogawa, T.; Takeda, K.; Akira, S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity, 1999, 11(1), 115-122.
23. Medzhitov, R.; Preston-Hurlburt, P.; Kopp, E.; Stadlen, A.; Chen, C.; Ghosh, S.; Janeway, C. A., Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell, 1998, 2(2), 253-258.
24. Takeuchi, O.; Takeda, K.; Hoshino, K.; Adachi, O.; Ogawa, T.; Akira, S. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int. Immunol., 2000, 12(1), 113-117.
25. Yamamoto, M.; Sato, S.; Hemmi, H.; Hoshino, K.; Kaisho, T.; Sanjo, H.; Takeuchi, O.; Sugiyama, M.; Okabe, M.; Takeda, K.; Akira, S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 2003, 301(5633), 640-643.
26. Honda, K.; Yanai, H.; Mizutani, T.; Negishi, H.; Shimada, N.; Suzuki, N.; Ohba, Y.; Takaoka, A.; Yeh, W. C.; Taniguchi, T. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. USA., 2004, 101(43), 15416-15421.
27. Sato, S.; Sugiyama, M.; Yamamoto, M.; Watanabe, Y.; Kawai, T.; Takeda, K.; Akira, S. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol., 2003, 171(8), 4304-4310.
28. Oshiumi, H.; Matsumoto, M.; Funami, K.; Akazawa, T.; Seya, T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat. Immunol., 2003, 4(2), 161-167.
29. Fitzgerald, K. A.; McWhirter, S. M.; Faia, K. L.; Rowe, D. C.; Latz, E.; Golenbock, D. T.; Coyle, A. J.; Liao, S. M.; Maniatis, T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol., 2003, 4(5), 491-496.
30. Ohnishi, H.; Tochio, H.; Kato, Z.; Orii, K. E.; Li, A.; Kimura, T.; Hiroaki, H.; Kondo, N.; Shirakawa, M. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc. Natl. Acad. Sci. USA., 2009, 106(25), 10260-10265.
31. Kollewe, C.; Mackensen, A. C.; Neumann, D.; Knop, J.; Cao, P.; Li, S.; Wesche, H.; Martin, M. U. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J. Biol. Chem., 2004, 279(7), 5227-5236.
32. Burns, K.; Janssens, S.; Brissoni, B.; Olivos, N.; Beyaert, R.; Tschopp, J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med., 2003, 197(2), 263-268.
33. Janssens, S.; Burns, K.; Tschopp, J.; Beyaert, R. Regulation of interleukin-1-and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr. Biol., 2002, 12(6), 467-471.
34. Avbelj, M.; Horvat, S.; Jerala, R. The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs. J. Immunol., 2011, 187(5), 2394-2404.
35. Lin, S. C.; Lo, Y. C.; Wu, H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature, 2010, 465(7300), 885-890.
36. Fekonja, O.; Bencina, M.; Jerala, R. Toll/interleukin-1 receptor domain dimers as the platform for activation and enhanced inhibition of Toll-like receptor signaling. J. Biol. Chem., 2012.
37. Fitzgerald, K. A.; Palsson-McDermott, E. M.; Bowie, A. G.; Jefferies, C. A.; Mansell, A. S.; Brady, G.; Brint, E.; Dunne, A.; Gray, P.; Harte, M. T.; McMurray, D.; Smith, D. E.; Sims, J. E.; Bird, T. A.; O'Neill, L. A. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature, 2001, 413(6851), 78-83.
38. Dunne, A.; Ejdeback, M.; Ludidi, P. L.; O'Neill, L. A.; Gay, N. J. Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J. Biol. Chem., 2003, 278(42), 41443-41451.
39. Valkov, E.; Stamp, A.; Dimaio, F.; Baker, D.; Verstak, B.; Roversi, P.; Kellie, S.; Sweet, M. J.; Mansell, A.; Gay, N. J.; Martin, J. L.; Kobe, B. Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc. Natl. Acad. Sci. USA., 2011, 108(36), 14879-14884.
40. Lin, Z.; Lu, J.; Zhou, W.; Shen, Y. Structural insights into TIR domain specificity of the bridging adaptor Mal in TLR4 signaling. PLoS One, 2012, 7(4), e34202.
41. Jiang, Z.; Mak, T. W.; Sen, G.; Li, X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc. Natl. Acad. Sci. USA, 2004, 101(10), 3533-3538.
42. Kagan, J. C.; Su, T.; Horng, T.; Chow, A.; Akira, S.; Medzhitov, R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol., 2008, 9(4), 361-368.
43. Rowe, D. C.; McGettrick, A. F.; Latz, E.; Monks, B. G.; Gay, N. J.; Yamamoto, M.; Akira, S.; O'Neill, L. A.; Fitzgerald, K. A.; Golenbock, D. T. The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc. Natl. Acad. Sci. USA., 2006, 103(16), 6299-6304.
44. Zhang, Q.; Zmasek, C. M.; Cai, X.; Godzik, A. TIR domaincontaining adaptor SARM is a late addition to the ongoing microbe-host dialog. Dev. Comp. Immunol., 2011, 35(4), 461-468.
45. Xu, Y.; Tao, X.; Shen, B.; Horng, T.; Medzhitov, R.; Manley, J. L.; Tong, L. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature, 2000, 408(6808), 111-115.
46. Nyman, T.; Stenmark, P.; Flodin, S.; Johansson, I.; Hammarstrom, M.; Nordlund, P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J. Biol. Chem., 2008, 283(18), 11861-11865.
47. Khan, J. A.; Brint, E. K.; O'Neill, L. A.; Tong, L. Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J. Biol. Chem., 2004, 279(30), 31664-31670.
48. Panter, G.; Jerala, R. The ectodomain of the Toll-like receptor 4 prevents constitutive receptor activation. J. Biol. Chem., 2011, 286(26), 23334-23344.
49. Underhill, D. M.; Ozinsky, A.; Hajjar, A. M.; Stevens, A.; Wilson, C. B.; Bassetti, M.; Aderem, A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature, 1999, 401(6755), 811-815.
50. Poltorak, A.; He, X.; Smirnova, I.; Liu, M. Y.; Van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi-Castagnoli, P.; Layton, B.; Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 1998, 282(5396), 2085-2088.
51. Fitzgerald, K. A.; Rowe, D. C.; Barnes, B. J.; Caffrey, D. R.; Visintin, A.; Latz, E.; Monks, B.; Pitha, P. M.; Golenbock, D. T. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J. Exp. Med., 2003, 198(7), 1043-1055.
52. Rhee, S. H.; Hwang, D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J. Biol. Chem., 2000, 275(44), 34035-34040.
53. Ronni, T.; Agarwal, V.; Haykinson, M.; Haberland, M. E.; Cheng, G.; Smale, S. T. Common interaction surfaces of the toll-like receptor 4 cytoplasmic domain stimulate multiple nuclear targets. Mol. Cell Biol., 2003, 23(7), 2543-2555.
54. Li, C.; Zienkiewicz, J.; Hawiger, J. Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J. Biol. Chem., 2005, 280(28), 26152-26159.
55. Jiang, Z.; Georgel, P.; Li, C.; Choe, J.; Crozat, K.; Rutschmann, S.; Du, X.; Bigby, T.; Mudd, S.; Sovath, S.; Wilson, I. A.; Olson, A.; Beutler, B. Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc. Natl. Acad. Sci. USA., 2006, 103(29), 10961-10966.
56. Nunez Miguel, R.; Wong, J.; Westoll, J. F.; Brooks, H. J.; O'Neill, L. A.; Gay, N. J.; Bryant, C. E.; Monie, T. P. A dimer of the Tolllike receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS One, 2007, 2(8), e788.
57. Cohen, J. The immunopathogenesis of sepsis. Nature, 2002, 420(6917), 885-891.
58. Andreakos, E.; Foxwell, B.; Feldmann, M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol. Rev., 2004, 202, 250-265.
59. Ulevitch, R. J. Therapeutics targeting the innate immune system. Nat. Rev. Immunol., 2004, 4(7), 512-520.
60. Joosten, L. A.; Koenders, M. I.; Smeets, R. L.; Heuvelmans-Jacobs, M.; Helsen, M. M.; Takeda, K.; Akira, S.; Lubberts, E.; van de Loo, F. A.; van den Berg, W. B. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J. Immunol., 2003, 171(11), 6145-6153.
61. Shishido, T.; Nozaki, N.; Yamaguchi, S.; Shibata, Y.; Nitobe, J.; Miyamoto, T.; Takahashi, H.; Arimoto, T.; Maeda, K.; Yamakawa, M.; Takeuchi, O.; Akira, S.; Takeishi, Y.; Kubota, I. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation, 2003, 108(23), 2905-2910.
62. Oyama, J.; Blais, C., Jr.; Liu, X.; Pu, M.; Kobzik, L.; Kelly, R. A.; Bourcier, T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation, 2004, 109(6), 784-789.
63. Michelsen, K. S.; Wong, M. H.; Shah, P. K.; Zhang, W.; Yano, J.; Doherty, T. M.; Akira, S.; Rajavashisth, T. B.; Arditi, M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA., 2004, 101(29), 10679-10684.
64. Bjorkbacka, H.; Kunjathoor, V. V.; Moore, K. J.; Koehn, S.; Ordija, C. M.; Lee, M. A.; Means, T.; Halmen, K.; Luster, A. D.; Golenbock, D. T.; Freeman, M. W. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med., 2004, 10(4), 416-421.
65. Kiechl, S.; Lorenz, E.; Reindl, M.; Wiedermann, C. J.; Oberhollenzer, F.; Bonora, E.; Willeit, J.; Schwartz, D. A. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med., 2002, 347(3), 185-192.
66. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol., 2006, 6(11), 823-835.
67. Leadbetter, E. A.; Rifkin, I. R.; Hohlbaum, A. M.; Beaudette, B. C.; Shlomchik, M. J.; Marshak-Rothstein, A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Tolllike receptors. Nature, 2002, 416(6881), 603-607.
68. Couillin, I.; Vasseur, V.; Charron, S.; Gasse, P.; Tavernier, M.; Guillet, J.; Lagente, V.; Fick, L.; Jacobs, M.; Coelho, F. R.; Moser, R.; Ryffel, B. IL-1R1/MyD88 signaling is critical for elastaseinduced lung inflammation and emphysema. J. Immunol., 2009, 183(12), 8195-8202.
69. Chen, C. J.; Shi, Y.; Hearn, A.; Fitzgerald, K.; Golenbock, D.; Reed, G.; Akira, S.; Rock, K. L. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest., 2006, 116(8), 2262-2271.
70. Martinon, F.; Petrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440(7081), 237-241.
71. Wen, L.; Ley, R. E.; Volchkov, P. Y.; Stranges, P. B.; Avanesyan, L.; Stonebraker, A. C.; Hu, C.; Wong, F. S.; Szot, G. L.; Bluestone, J. A.; Gordon, J. I.; Chervonsky, A. V. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature, 2008, 455(7216), 1109-1113.
72. Kleinridders, A.; Schenten, D.; Konner, A. C.; Belgardt, B. F.; Mauer, J.; Okamura, T.; Wunderlich, F. T.; Medzhitov, R.; Bruning, J. C. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and dietinduced obesity. Cell Metab., 2009, 10(4), 249-259.
73. Alfonso-Loeches, S.; Pascual-Lucas, M.; Blanco, A. M.; Sanchez-Vera, I.; Guerri, C. Pivotal role of TLR4 receptors in alcoholinduced neuroinflammation and brain damage. J. Neurosci., 2010, 30(24), 8285-8295.
74. Racke, M. K.; Drew, P. D. Toll-like receptors in multiple sclerosis. Curr. Top. Microbiol. Immunol., 2009, 336, 155-168.
75. Kitazawa, M.; Cheng, D.; Tsukamoto, M. R.; Koike, M. A.; Wes, P. D.; Vasilevko, V.; Cribbs, D. H.; LaFerla, F. M. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J. Immunol., 2011, 187(12), 6539-6549.
76. Huang, B.; Zhao, J.; Li, H.; He, K. L.; Chen, Y.; Chen, S. H.; Mayer, L.; Unkeless, J. C.; Xiong, H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res., 2005, 65(12), 5009-5014.
77. Kelly, M. G.; Alvero, A. B.; Chen, R.; Silasi, D. A.; Abrahams, V. M.; Chan, S.; Visintin, I.; Rutherford, T.; Mor, G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res., 2006, 66(7), 3859-3868.
78. Rakoff-Nahoum, S.; Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science, 2007, 317(5834), 124-127.
79. Kanzler, H.; Barrat, F. J.; Hessel, E. M.; Coffman, R. L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med., 2007, 13(5), 552-559.
80. Rossignol, D. P.; Lynn, M. TLR4 antagonists for endotoxemia and beyond. Curr. Opin. Investig. Drugs, 2005, 6(5), 496-502.
81. Spiller, S.; Elson, G.; Ferstl, R.; Dreher, S.; Mueller, T.; Freudenberg, M.; Daubeuf, B.; Wagner, H.; Kirschning, C. J. TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J. Exp. Med., 2008, 205(8), 1747-1754.
82. Kalia, S.; Dutz, J. P. New concepts in antimalarial use and mode of action in dermatology. Dermatol. Ther., 2007, 20(4), 160-174.
83. Kim, W. U.; Sreih, A.; Bucala, R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun. Rev., 2009, 8(3), 204-208.
84. Barrat, F. J.; Meeker, T.; Chan, J. H.; Guiducci, C.; Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol., 2007, 37(12), 3582-3586.
85. Karin, M.; Yamamoto, Y.; Wang, Q. M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov., 2004, 3(1), 17-26.
86. Karin, M. Inflammation-activated protein kinases as targets for drug development. Proc. Am. Thorac. Soc., 2005, 2(4), 386-390. discussion 394-385.
87. Wang, Z.; Wesche, H.; Stevens, T.; Walker, N.; Yeh, W. C. IRAK-4 inhibitors for inflammation. Curr. Top. Med. Chem., 2009, 9(8), 724-737.
88. Brint, E. K.; Xu, D.; Liu, H.; Dunne, A.; McKenzie, A. N.; O'Neill, L. A.; Liew, F. Y. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol., 2004, 5(4), 373-379.
89. Qin, J. Z.; Qian, Y. C.; Yao, J. H.; Grace, C.; Li, X. X. SIGIRR inhibits interleukin-1 receptor-and toll-like receptor 4-mediated signaling through different mechanisms. J. Biol. Chem., 2005, 280(26), 25233-25241.
90. Mansell, A.; Smith, R.; Doyle, S. L.; Gray, P.; Fenner, J. E.; Crack, P. J.; Nicholson, S. E.; Hilton, D. J.; O'Neill, L. A.; Hertzog, P. J. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol., 2006, 7(2), 148-155.
91. Bowie, A.; Kiss-Toth, E.; Symons, J. A.; Smith, G. L.; Dower, S. K.; O'Neill, L. A. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. USA., 2000, 97(18), 10162-10167.
92. Cirl, C.; Wieser, A.; Yadav, M.; Duerr, S.; Schubert, S.; Fischer, H.; Stappert, D.; Wantia, N.; Rodriguez, N.; Wagner, H.; Svanborg, C.; Miethke, T. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domaincontaining proteins. Nat. Med., 2008, 14(4), 399-406.
93. Newman, R. M.; Salunkhe, P.; Godzik, A.; Reed, J. C. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. Infect. Immun., 2006, 74(1), 594-601.
94. Gradisar, H.; Keber, M. M.; Pristovsek, P.; Jerala, R. MD-2 as the target of curcumin in the inhibition of response to LPS. J. Leukoc. Biol., 2007, 82(4), 968-974.
95. Mancek-Keber, M.; Gradisar, H.; Inigo Pestana, M.; Martinez de Tejada, G.; Jerala, R. Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. J. Biol. Chem., 2009, 284(29), 19493-19500.
96. Mancek-Keber, M.; Jerala, R. Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2. FASEB J., 2006, 20(11), 1836-1842.
97. Resman, N.; Gradisar, H.; Vasl, J.; Keber, M. M.; Pristovsek, P.; Jerala, R. Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS Lett., 2008, 582(28), 3929-3934.
98. Kerkis, A.; Hayashi, M. A.; Yamane, T.; Kerkis, I. Properties of cell penetrating peptides (CPPs). IUBMB Life, 2006, 58(1), 7-13.
99. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem., 2001, 276(8), 5836-5840.
100. Kalderon, D.; Roberts, B. L.; Richardson, W. D.; Smith, A. E. A short amino acid sequence able to specify nuclear location. Cell, 1984, 39(3 Pt 2), 499-509.
101. Schutze-Redelmeier, M. P.; Gournier, H.; Garcia-Pons, F.; Moussa, M.; Joliot, A. H.; Volovitch, M.; Prochiantz, A.; Lemonnier, F. A. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J. Immunol., 1996, 157(2), 650-655.
102. Schwarze, S. R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285(5433), 1569-1572.
103. Nir, S.; Nieva, J. L. Interactions of peptides with liposomes: pore formation and fusion. Prog. Lipid Res., 2000, 39(2), 181-206.
104. Mishra, A.; Lai, G. H.; Schmidt, N. W.; Sun, V. Z.; Rodriguez, A. R.; Tong, R.; Tang, L.; Cheng, J.; Deming, T. J.; Kamei, D. T.; Wong, G. C. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc. Natl. Acad. Sci. USA., 2011, 108(41), 16883-16888.
105. Nelson, A. R.; Borland, L.; Allbritton, N. L.; Sims, C. E. Myristoyl-based transport of peptides into living cells. Biochemistry, 2007, 46(51), 14771-14781.
106. Letoha, T.; Kusz, E.; Papai, G.; Szabolcs, A.; Kaszaki, J.; Varga, I.; Takacs, T.; Penke, B.; Duda, E. In vitro and in vivo nuclear factorkappaB inhibitory effects of the cell-penetrating penetratin peptide. Mol. Pharmacol., 2006, 69(6), 2027-2036.
107. Toshchakov, V. U.; Basu, S.; Fenton, M. J.; Vogel, S. N. Differential involvement of BB loops of toll-IL-1 resistance (TIR) domain-containing adapter proteins in TLR4-versus TLR2-mediated signal transduction. J. Immunol., 2005, 175(1), 494-500.
108. Toshchakov, V. Y.; Fenton, M. J.; Vogel, S. N. Cutting Edge: Differential inhibition of TLR signaling pathways by cellpermeable peptides representing BB loops of TLRs. J. Immunol., 2007, 178(5), 2655-2660.
109. Toshchakov, V. Y.; Vogel, S. N. Cell-penetrating TIR BB loop decoy peptides a novel class of TLR signaling inhibitors and a tool to study topology of TIR-TIR interactions. Expert. Opin. Biol. Ther., 2007, 7(7), 1035-1050.
110. Toshchakov, V. Y.; Szmacinski, H.; Couture, L. A.; Lakowicz, J. R.; Vogel, S. N. Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface. J. Immunol., 2011, 186(8), 4819-4827.
111. Couture, L. A.; Piao, W.; Ru, L. W.; Vogel, S. N.; Toshchakov, V. Y. Targeting Toll-like receptor (TLR) signaling by Toll/IL-1R domain-containing adapter protein/MyD88-adapter-like-(TIRAP/Mal-) derived decoy peptides. J. Biol. Chem., 2012.
112. Jeyaseelan, S.; Manzer, R.; Young, S. K.; Yamamoto, M.; Akira, S.; Mason, R. J.; Worthen, G. S. Toll-IL-1 receptor domaincontaining adaptor protein is critical for early lung immune responses against Escherichia coli lipopolysaccharide and viable Escherichia coli. J. Immunol., 2005, 175(11), 7484-7495.
113. Loiarro, M.; Ruggiero, V.; Sette, C. Targeting TLR/IL-1R signalling in human diseases. Mediators Inflamm., 2010, 674363.
114. Loiarro, M.; Sette, C.; Gallo, G.; Ciacci, A.; Fanto, N.; Mastroianni, D.; Carminati, P.; Ruggiero, V. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B. J. Biol. Chem., 2005, 280(16), 15809-15814.
115. Egunsola, A. T.; Zawislak, C. L.; Akuffo, A. A.; Chalmers, S. A.; Ewer, J. C.; Vail, C. M.; Lombardo, J. C.; Perez, D. N.; Kurt, R. A. Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88. Cell Immunol., 2012, 272(2), 220-229.
116. Lysakova-Devine, T.; Keogh, B.; Harrington, B.; Nagpal, K.; Halle, A.; Golenbock, D. T.; Monie, T.; Bowie, A. G. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J. Immunol., 2010, 185(7), 4261-4271.
117. Stack, J.; Haga, I. R.; Schroder, M.; Bartlett, N. W.; Maloney, G.; Reading, P. C.; Fitzgerald, K. A.; Smith, G. L.; Bowie, A. G. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med., 2005, 201(6), 1007-1018.
118. Japelj, B.; Pristovsek, P.; Majerle, A.; Jerala, R. Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrinbased peptide. J. Biol. Chem., 2005, 280(17), 16955-16961.
119. Mancek, M.; Pristovsek, P.; Jerala, R. Identification of LPSbinding peptide fragment of MD-2, a toll-receptor accessory protein. Biochem. Biophys. Res. Commun., 2002, 292(4), 880-885.
120. Mancek-Keber, M.; Bencina, M.; Japelj, B.; Panter, G.; Andra, J.; Brandenburg, K.; Triantafilou, M.; Triantafilou, K.; Jerala, R. MARCKS as a negative regulator of lipopolysaccharide signaling. J. Immunol., 2012, 188(8), 3893-3902.
121. Zorko, M.; Japelj, B.; Hafner-Bratkovic, I.; Jerala, R. Expression, purification and structural studies of a short antimicrobial peptide. Biochim. Biophys. Acta., 2009, 1788(2), 314-323.
122. Bartfai, T.; Behrens, M. M.; Gaidarova, S.; Pemberton, J.; Shivanyuk, A.; Rebek, J., Jr. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptormediated responses. Proc. Natl. Acad. Sci. USA, 2003, 100(13), 7971-7976.
123. Davis, C. N.; Mann, E.; Behrens, M. M.; Gaidarova, S.; Rebek, M.; Rebek, J., Jr.; Bartfai, T. MyD88-dependent and-independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc. Natl. Acad. Sci. USA, 2006, 103(8), 2953-2958.
124. Loiarro, M.; Capolunghi, F.; Fanto, N.; Gallo, G.; Campo, S.; Arseni, B.; Carsetti, R.; Carminati, P.; De Santis, R.; Ruggiero, V.; Sette, C. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J. Leukoc. Biol., 2007, 82(4), 801-810.
125. Van Tassell, B. W.; Seropian, I. M.; Toldo, S.; Salloum, F. N.; Smithson, L.; Varma, A.; Hoke, N. N.; Gelwix, C.; Chau, V.; Abbate, A. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J. Cardiovasc. Pharmacol., 2010, 55(4), 385-390.
126. Capolunghi, F.; Rosado, M. M.; Cascioli, S.; Girolami, E.; Bordasco, S.; Vivarelli, M.; Ruggiero, B.; Cortis, E.; Insalaco, A.; Fanto, N.; Gallo, G.; Nucera, E.; Loiarro, M.; Sette, C.; De Santis, R.; Carsetti, R.; Ruggiero, V. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatol. (Oxford), 2010, 49(12), 2281-2289.
127. Kawamoto, T.; Ii, M.; Kitazaki, T.; Iizawa, Y.; Kimura, H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur. J. Pharmacol., 2008, 584(1), 40-48.
128. Matsunaga, N.; Tsuchimori, N.; Matsumoto, T.; Ii, M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol. Pharmacol., 2011, 79(1), 34-41.
129. Sha, T.; Sunamoto, M.; Kitazaki, T.; Sato, J.; Ii, M.; Iizawa, Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur. J. Pharmacol., 2007, 571(2-3), 231-239.
130. Yamamoto, M.; Sato, S.; Mori, K.; Hoshino, K.; Takeuchi, O.; Takeda, K.; Akira, S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFNbeta promoter in the Toll-like receptor signaling. J. Immunol., 2002, 169(12), 6668-6672.
131. Monaco, C.; Gregan, S. M.; Navin, T. J.; Foxwell, B. M.; Davies, A. H.; Feldmann, M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation, 2009, 120(24), 2462-2469.
132. Burns, K.; Martinon, F.; Esslinger, C.; Pahl, H.; Schneider, P.; Bodmer, J. L.; Di Marco, F.; French, L.; Tschopp, J. MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem., 1998, 273(20), 12203-12209.
133. Sacre, S. M.; Andreakos, E.; Kiriakidis, S.; Amjadi, P.; Lundberg, A.; Giddins, G.; Feldmann, M.; Brennan, F.; Foxwell, B. M. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am. J. Pathol., 2007, 170(2), 518-525.
134. Ulrichts, P.; Peelman, F.; Beyaert, R.; Tavernier, J. MAPPIT analysis of TLR adaptor complexes. FEBS Lett., 2007, 581(4), 629-636.
135. Mandrup-Poulsen, T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia, 1996, 39(9), 1005-1029.
136. Dupraz, P.; Cottet, S.; Hamburger, F.; Dolci, W.; Felley-Bosco, E.; Thorens, B. Dominant negative MyD88 proteins inhibit interleukin-1beta /interferon-gamma-mediated induction of nuclear factor kappa B-dependent nitrite production and apoptosis in beta cells. J. Biol. Chem., 2000, 275(48), 37672-37678.
137. Sacre, S. M.; Lundberg, A. M.; Andreakos, E.; Taylor, C.; Feldmann, M.; Foxwell, B. M. Selective use of TRAM in lipopolysaccharide (LPS) and lipoteichoic acid (LTA) induced NFkappaB activation and cytokine production in primary human cells: TRAM is an adaptor for LPS and LTA signaling. J. Immunol., 2007, 178(4), 2148-2154.
138. Hua, F.; Ha, T.; Ma, J.; Gao, X.; Kelley, J.; Williams, D. L.; Browder, I. W.; Kao, R. L.; Li, C. Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem. Biophys. Res. Commun., 2005, 338(2), 1118-1125.
139. Bovijn, C.; Ulrichts, P.; De Smet, A. S.; Catteeuw, D.; Beyaert, R.; Tavernier, J.; Peelman, F. Identification of interaction sites for dimerization and adapter recruitment in Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 4. J. Biol. Chem., 2012, 287(6), 4088-4098.
140. Kabouridis, P. S. Biological applications of protein transduction technology. Trends Biotechnol., 2003, 21(11), 498-503.
141. Funami, K.; Sasai, M., Oshiumi, H.; Seya, T.; Matsumoto, M. Homo-oligomerization is essential for Toll/interleukin-1 receptor domain-containing adaptor molecule-1-mediated NF-kappaB and interferon regulatory factor-3 activation. J. Biol. Chem., 2008, 283(26), 18283-18291.